BioCentury
ARTICLE | Company News

FDA accepts BLA for Novartis' AMD therapy

April 15, 2019 9:50 PM UTC

Novartis said FDA accepted for review a BLA for brolucizumab to treat wet age-related macular degeneration. The pharma said it used a Priority Review voucher for the application, but declined to disclose details about the voucher.

Novartis AG (NYSE:NVS; SIX:NOVN) hopes to launch the next-generation, humanized single-chain anti-VEGF antibody fragment in the U.S. by year end...

BCIQ Company Profiles

Novartis AG